Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel

Showing results (291-300 of 459) with videos related to

Pageof 46
Sort By:
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Academic Pediatrics|October 28, 2023
Associations Between Adverse Childhood Experiences and Early Adolescent Physical Activity in the United StatesAbubakr A A Al-Shoaibi, Puja Iyra, Julia H Raney, et al.
European Heart Journal. Acute Cardiovascular Care|February 25, 2022
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trialGorav Batra, Henrik Renlund, Vijay Kunadian, et al.
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Critical Pathways in Cardiology|September 4, 2009
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH RegistryAmit Kumar, Gregg C Fonarow, Kim A Eagle, et al.
Circulation|May 14, 2003
Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarctionLaurent J Feldman, Pierre Coste, Alain Furber, et al.
American Heart Journal|December 5, 2009
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationEdoardo Camenzind, William Wijns, Laura Mauri, et al.
JAMA|January 13, 2006
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosisDeepak L Bhatt, P Gabriel Steg, E Magnus Ohman, et al.
Pageof 46

Showing results (291-300 of 459) with videos related to

Sort By:
Pageof 46
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Academic Pediatrics|October 28, 2023
Associations Between Adverse Childhood Experiences and Early Adolescent Physical Activity in the United StatesAbubakr A A Al-Shoaibi, Puja Iyra, Julia H Raney, et al.
European Heart Journal. Acute Cardiovascular Care|February 25, 2022
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trialGorav Batra, Henrik Renlund, Vijay Kunadian, et al.
American Heart Journal|July 12, 2011
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialJeffrey S Berger, Deepak L Bhatt, P Gabriel Steg, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Critical Pathways in Cardiology|September 4, 2009
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH RegistryAmit Kumar, Gregg C Fonarow, Kim A Eagle, et al.
Circulation|May 14, 2003
Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarctionLaurent J Feldman, Pierre Coste, Alain Furber, et al.
American Heart Journal|December 5, 2009
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantationEdoardo Camenzind, William Wijns, Laura Mauri, et al.
JAMA|January 13, 2006
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosisDeepak L Bhatt, P Gabriel Steg, E Magnus Ohman, et al.
Pageof 46